Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy

Alterations in phosphorylation of cellular proteins are a hallmark of malignant transformation. Degradation of these phosphoproteins could generate cancer-specific class I MHC-associated phosphopepticles recognizable by CD8(+) T lymphocytes. In a comparative analysis of phosphopeptides presented on the surface of melanoma, ovarian carcinoma, and B lymphoblastoid cells, we find 5 of 36 that are restricted to the solid tumors and common to both cancers. Differential presentation of these peptides can result from differential phosphorylation of the source proteins. Recognition of the peptides on cancer cells by phosphopepticle-specific CD8(+) T lymphocytes validates the potential of these phosphopeptides as immunotherapeutic targets.